Cochlear (ASX:COH) has today announced that it has received US Food and Drug Administration approval for its new Nucleus Profile Plus Series implant.
The company says it will commence an immediate US launch.
The implant is designed for routine MRI scans without the need to remove the internal magnet.
Commercial availability has already commenced in Germany with other European countries to follow over the coming months.
It's good news for the hearing implants company after it suffered a lower rate of growth and loss of share in the US earlier this year due to a competitor product launch.
Shares in Cochlear (ASX:COH) are trading 0.64 per cent lower at $202.92.